 Home > Active Ingredient News > Immunology News > NEJM: Antibiotic secondary prevention for latent rheumatic heart disease

NEJM: Antibiotic secondary prevention for latent rheumatic heart disease

 Last Update: 2022-02-18
 Source: Internet
 Author: User

Tags

mano disease

antibiotic metronidazole

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

More than 40.

Screening for antibiotic prophylaxis

Researchers conducted a randomized controlled trial of antibiotic secondary prevention in Ugandan children and adolescents aged 5 to 17 years with latent rheumatic heart disease, according to a study published in the top medical journal NEJM

child

All participants underwent echocardiography at baseline and 2 years after randomization

Of the 102,200 children and adolescents screened by echocardiography, 3327 subjects were initially assessed to have latent rheumatic heart disease, and 926 of the 3327 subjects were subsequently diagnosed by echocardiography, and was determined to meet the test conditions

CONCLUSIONS: In children and adolescents aged 5 to 17 years with latent rheumatic heart disease, antibiotic secondary prevention reduces the risk of disease progression at 2 years

Antibiotic secondary prophylaxis reduces 2-year risk of disease progression in children and adolescents aged 5 to 17 years with latent rheumatic heart disease

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.